Primate research in 2018
Primate research: quality trumps over quantity
Through recent years the use of monkeys in European research has been . Most recently, a UK government noted the number of primate experiments had fallen for the third consecutive year. Researchers suspect that a combination of increasing regulatory pressure, rising costs, and disapproval among the public are responsible. Some countries, such as the Netherlands and Belgium, have even taken political measures to deliberately scale back on primate research.
However, non-human primate research has allowed for immeasurable progress in many areas of medicine. From treatments for Parkinson’s disease and HIV to reducing cholesterol, research using non-human primates has been undeniably saving lives. Throughout this year, more fundamental breakthroughs were made possible that will change human lives.
Primate research on the forefront of heart disease
The most recent example is taking us a step closer to transplanting pig hearts into humans. After , researchers from Germany, Sweden and Switzerland believe that clinical trials of pig organs in humans could begin in as little as in three years. This wasn’t the first time pig organs, including hearts, had been transplanted into monkeys. Previous work has showed that a pig heart can function for more than two and a half years when transplanted into the abdomen of a baboon – although the baboon kept its own heart to pump blood around its body. In a world where people are dying because there are not enough organs to transplant, this procedure could save thousands.
This wasn’t the only battle won against heart disease. For the first time, American researchers used to disable a gene throughout much of the liver. This approach , suggesting a treatment for heart disease. The study could also pave the way for treating certain genetic diseases caused by a defective, havoc-causing protein. Gene edited primates are nothing new. China has used the famous CRISPR DNA scissors in monkey embryos to for studying diseases. Many gene-editing tools are currently being tested, however, so it’s too early to tell which of those approaches will be used in into people.
The battle against viruses
This year was also marked by impressive progress towards an HIV vaccine. Despite enormous efforts over more than 30 years that have led to life-saving treatments for HIV/AIDS, researchers have yet to develop either a vaccine or cure for the disease; but they have made progress in monkey experiments. Several AIDS vaccines have had some success in monkey models, which typically use SIV, a simian cousin of HIV that causes AIDS in rhesus macaques.
One vaccine has from the pack. Designed by Louis Picker and American colleagues, the vaccine stitches SIV genes into a harmless Trojan horse, cytomegalovirus. Picker’s team has given the vaccine to more than 200 monkeys and then “challenged” them with injections of a particularly nasty strain of SIV. All told, 55% of the animals became temporarily infected and then completely controlled the virus for years or even cleared it from their system completely. However, they have yet to nail down the immune responses that explain the vaccine’s success, and they also can’t explain why it frequently fails. However, this year, American . identified with 91% accuracy whether the vaccine injection would protect an animal, offering new ways to tweak the vaccine.
In another promising study American scientists tested various combinations of a mosaic vaccine in people who did not have HIV and were healthy. All of the vaccine combinations and were found to be safe. The scientists also carried out a parallel study where they gave rhesus monkeys the vaccine to protect them from SIV. The mosaic vaccine combination that showed the most promise in humans was found to from getting the disease.
In another study with a hybrid of SIV and HIV called SHIV. After treating all the animals with different anti-retrovirals (ARVs) for 2 years and then stopping, the monkeys that had received a drug that binds to toll-like receptor 7 (TLR7) and a potent HIV antibody that studs innate immune system cells showed very encouraging results as the SHIV didn’t return in the animals after 6 months. The research is still continueing.
However, HIV isn’t the only virus subject to non-human primate research. We may be a step closer to getting rid of genital herpes for example. Two vaccines that are about to go into clinical trials have proven to be safe and effective in guinea pigs and monkeys.
The production of as many as 1,000 doses of an against Ebola has has already been is underway.
One more example is in the fight against the Zika virus and in a recent study, a first of its kind to really show how pathogenic Zika can be in infants,.while the devastating developmental damage that Zika infection can cause when children are infected in the womb is abundantly clear, the question remains: what about babies infected shortly after birth? To gain some insight, researchers infected infant with Zika virus after they were born, and and display atypical behaviour at six months of age.
Primate research will always benefit neuroscience
And last, but not least among the most remarkable stories of this year regarding non-human primate research is the study of the brain and the spinal cord. Unsurprisingly, primate, including humans, have , making monkeys an essential model to understand how the brain functions and to study neuro-degenerative disorders such as Parkinson’s or Alzheimer’s disease.
This year, Researchers at the Texas Biomedical Research Institute have identified that mimics the sleep disturbances, changes in circadian rhythm, and cognitive impairment seen in people with Parkinson's disease. This nonhuman primate model mimics additional various types of tremors, such as action tremor, rest and postural tremors, as well as cognitive deficits, sleep and circadian rhythm disturbances and side effects of drug treatment, such as the involuntary movements known as dyskinesia that appear after long-term L-dopa therapy. Thanks to these new models, it is possible to take Parkinson’s research one step further. In China this year for example, scientists report after grafting dopamine neurons derived from embryonic stem cells (ESCs) into their brains. The stem cell–derived transplants were stable for 24 months and led to wide-ranging behavioural improvements in the monkey. The findings will serve as preclinical data for China’s first ESC-based clinical study for the neurological disease.
A few months later, tests on humans were already giving results. Japanese researchers tested for the first time the use of reprogrammed stem cells in the human brain. They into the brain of a man with Parkinson’s disease. A very similar procedure in monkeys whose dopaminergic neurons had been experimentally poisoned to model Parkinson’s disease. This is the first time that researchers tested the use of iPSCs in the human brain, and Parkinson’s disease is only among a handful of conditions for which iPSC-based therapies have been tested in humans at all. The transplanted cells in this treatment are precursors to dopamine-producing neurons, and the hope is that they will restore the dopamine deficit and relieve symptoms.
The use of stem cells isn’t only useful against Parkinson’s disease. A recent study has shown that . Human neural stem cells transplanted into the injured spines of monkeys matured into nerve cells, spurring neuronal connections and giving the animals an improved ability to grasp an orange. Up to this point, most of the work on transplanting neural stem cells had been done in rats. This is the first study to show the treatment can be successfully scaled up to primates.
The future of primate research
2018 has been a remarkable year for primate research, with a few first time studies and some concrete translations to humans. So what are we to expect in the years to come? No doubt continued progress in making vaccines to protect against diseases such as HIV and also further steps towards the promise of using impacted cells to repair the damage of accidents and old age.